TRASCO: Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients

Sponsor
University Hospital Tuebingen (Other)
Overall Status
Unknown status
CT.gov ID
NCT00902109
Collaborator
Alcon Research (Industry)
12
1
80
0.1

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the two psychophysical perimetric techniques regarding progression of the visual field.

Condition or Disease Intervention/Treatment Phase
  • Device: Perimetry
  • Device: Confocal Scanning Laser Tomography
  • Device: Optical Coherence Tomography (OCT)

Study Design

Study Type:
Observational
Anticipated Enrollment :
12 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Pilot Study to Compare the Humphrey Field Analyzer (HFA) 30-2 Swedish Interactive Threshold Algorithm (SITA) Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE), Using a New Fast GATE (German Adaptive Threshold Estimation) in Glaucoma Patients Under Topic Therapy
Study Start Date :
Apr 1, 2010
Anticipated Primary Completion Date :
Dec 1, 2016
Anticipated Study Completion Date :
Dec 1, 2016

Arms and Interventions

Arm Intervention/Treatment
perimetry, HRT, OCT

perimetry, HRT, OCT

Device: Perimetry
different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
Other Names:
  • Humphrey Field Analyzer 745i (HFA), Interzeag Octopus 101
  • Device: Confocal Scanning Laser Tomography
    HRT examinations for the clinical evaluation of the optic disc.
    Other Names:
  • Heidelberg Retina Tomograph (HRT)
  • Device: Optical Coherence Tomography (OCT)
    imaging of the retinal nerve fiber layer
    Other Names:
  • Spectralis-OCT (Heidelberg Engineering, Heidelberg, Germany)
  • Outcome Measures

    Primary Outcome Measures

    1. Comparison of rate of progression [36 month]

      Perimetric measures every 3 month over 3 years

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • primary open angle glaucoma (POAG)

    • spherical ametropia max. ± 8 dpt

    • cylindrical ametropia max. ± 3 dpt

    • distant visual acuity > 10/20

    • pupil diameter > 3 mm

    Exclusion Criteria:
    • diabetic retinopathy

    • asthma

    • history of epilepsy or significant psychiatric disease

    • medications known to effect visual field sensitivity

    • infections (e.g., keratitis, conjunctivitis, uveitis)

    • severe dry eyes

    • miotic drug

    • squint

    • nystagmus

    • albinism

    • any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields

    • keratoconus

    • intraocular surgery (except for uncomplicated cataract surgery) performed < 3 month prior to screening

    • history or signs of any visual pathway affection other than glaucoma

    • history or presence of macular disease and/or macular edema, ocular trauma, medications known to affect visual field sensitivity

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Institute for Ophthalmic Research Tuebingen Germany 72076

    Sponsors and Collaborators

    • University Hospital Tuebingen
    • Alcon Research

    Investigators

    • Principal Investigator: Ulrich Schiefer, Prof. Dr. med., University Hospital Tuebingen

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ulrich Schiefer, Prof. Dr. med., University Hospital Tuebingen
    ClinicalTrials.gov Identifier:
    NCT00902109
    Other Study ID Numbers:
    • SCOPE-G-BETA
    First Posted:
    May 14, 2009
    Last Update Posted:
    Feb 2, 2016
    Last Verified:
    Jan 1, 2016
    Keywords provided by Ulrich Schiefer, Prof. Dr. med., University Hospital Tuebingen
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 2, 2016